EOLS
Evolus, Inc.NASDAQHealthcare$4.03-6.50%ClosedMarket Cap: $262.2M
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
-11.61
P/S
0.91
EV/EBITDA
-13.45
DCF Value
$9.52
FCF Yield
-17.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
65.8%
Operating Margin
-12.5%
Net Margin
-17.4%
ROE
267.8%
ROA
-22.9%
ROIC
-24.3%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $90.3M | $130.0K | $0.00 |
| FY 2025 | $297.2M | $-51.6M | $-0.80 |
| Q3 2025 | $69.0M | $-15.7M | $-0.24 |
| Q2 2025 | $69.4M | $-17.1M | $-0.27 |
Analyst Ratings
View AllBTIGBuy
2026-03-04HC Wainwright & Co.Buy
2026-02-03BTIGBuy
2026-01-22StifelBuy
2026-01-13NeedhamHold
2025-12-24Trading Activity
Insider Trades
View AllAvelar Ruiofficer: See Remarks
SellFri Mar 20
MOATAZEDI DAVIDdirector, officer: See Remarks
SellFri Mar 20
MOATAZEDI DAVIDdirector, officer: See Remarks
SellWed Mar 18
MOATAZEDI DAVIDdirector, officer: See Remarks
SellWed Mar 18
Avelar Ruiofficer: See Remarks
SellWed Mar 18
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.00
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.